Lipoprotein(a) Management
Diagnosis and Risk Assessment
- The American College of Cardiology recommends that lipoprotein(a) [Lp(a)] levels above 30 mg/dL or 75 nmol/L are considered elevated, representing approximately the 75th percentile in Caucasian populations, where cardiovascular risk begins to increase 1, 2
- In the general population without prior cardiovascular disease, the threshold for high cardiovascular risk is >20-25 mg/dL or >50-75 nmol/L 3, 2
- According to European guidelines, significant risk is defined when Lp(a) >50 mg/dL (approximately 100-125 nmol/L) 2, 4
- The Canadian guidelines use a cutoff of >30 mg/dL to define abnormal levels 1
Treatment and Management
- The primary management of patients with elevated Lp(a) is aggressive reduction of LDL-cholesterol to the lowest achievable level, with a target of LDL-C <70 mg/dL (1.8 mmol/L) 4, 6
- The American College of Cardiology recommends a stepped treatment approach, starting with high-intensity statin therapy, followed by the addition of ezetimibe if necessary, and consideration of PCSK9 inhibitors for high-risk patients 4, 6, 7
- Niacin reduces Lp(a) by 30-35% and is currently the most recommended medication specifically for Lp(a) reduction 6
- Lipoprotein apheresis reduces Lp(a) by up to 80% and should be considered in patients with Lp(a) >60 mg/dL who develop cardiovascular events or disease progression despite optimal medical therapy 6
Special Populations
- Children with elevated Lp(a) levels have a four-fold increased risk of acute ischemic stroke 5, 6
- Patients with chronic kidney disease have substantially increased Lp(a) levels and are at higher risk of cardiovascular events 5, 6
- Patients with familial hypercholesterolemia and elevated Lp(a) are at higher cardiovascular risk and may require more intensive LDL-C reduction with PCSK9 inhibitors or lipoprotein apheresis 6